A carregar...
What is the future of CCR5 antagonists in rheumatoid arthritis?
Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SC...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3446428/ https://ncbi.nlm.nih.gov/pubmed/22494450 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/ar3775 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|